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Abstract
Introduction: Thyroid cancer diagnosis is based mainly on fine needle aspiration biopsy (FNAB) performed under ultrasonography guid-
ance. Questions arise in cases of an inconclusive FNAB result — when there is no clear evidential data to support the existence of
a malignant lesion or when there are any other reasons which make the decision process difficult, such as the patient’s age or coexisting
diseases. To clarify this issue the patient should be encouraged to undergo surgery treatment or to be followed up. Thyroid scintigraphy
with an oncophilic tracer such as MIBI-Tc99m may be helpful.
Material and methods: The study comprised a group of 12 patients, aged 54–75 (av. 63.5) years, who, in 2009, underwent planar and
SPECT/CT thyroid scintigraphy with MIBI-Tc99m using washout method. The tumour/background ratio in early and delayed images was
calculated and the wash-out ratio was estimated. Patients with increased focal lesion uptake were operated on and the lesions were
histopathologically verified.
Results: Abnormal scintigraphy results were obtained in 8 patients (10 lesions) and normal results in 4 patients (5 lesions). Out of 15
studies, in 13 cases the washout from the lesion was observed within 2 hours. It was noticed that the images obtained with SPECT/CT
washout method were clearer and easier to read in comparison to planar studies.
Three patients with an abnormal results underwent surgery and had benign histopathology results after the operation, in 3 patients the
observation is being confirmed without any increase in malignancy suspicions, and 2 were lost for observation.
Conclusions: Our preliminary results do support the use of MIBI-Tc99m in the evaluation of indeterminate thyroid nodules. To validate the
hypothesis that MIBI-Tc99m may be used to exclude malignancy in lesions indeterminate by FNAB we propose to use SPECT-CT derived
images and standardized evaluation criteria. (Pol J Endocrinol 2010; 61 (5): 422–426)
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Streszczenie
Wstęp: Niediagnostyczne badania cytologiczne (FNAB, fine needle aspiration biopsy) guzków tarczycy lub inne przyczyny utrudniające podję-
cie decyzji o leczeniu operacyjnym tarczycy, takie jak wiek pacjenta lub zawansowanie choroby towarzyszące, stanowią poważną przyczynę
w ostatecznym wyborze posterowania, szczególnie jeżeli nie ma jednoznacznych danych wskazujących na obecność zmiany nowotworo-
wej. Dodatkowym sposobem wyjaśnienia charakteru zmiany jest badanie radioizotopowe z MIBI- Tc99m. Gromadzenie MIBI jest interpreto-
wane jako sygnał zwiększający ryzyko złośliwości, zwłaszcza gdy utrzymuje się przez dłuższy czas. W pracy postanowiono ocenić przydat-
ność badania scyntygraficznego SPECT/CT z MIBI-Tc99m metodą wymywania w relacji do wyników badania histopatologicznego.
Materiał i metody: W 2009 roku wykonano u 12 chorych w wieku 54–75 (śr. 63,5) lat badania scyntygraficzne tarczycy planarne oraz
SPECT/CT z MIBI-Tc99m, poprzedzone o badanie wymywania. Wyliczono wskaźniki wymywania i wskaźniki guz/tło w obrazach wcze-
snych i późnych. Chorzy ze wzmożonym wychwytem znacznika byli operowani i badani histopatologicznie.
Wyniki: Wzmożone gromadzenie MIBI-Tc99m obserwowano u 8 pacjentów (10 zmian), a brak gromadzenia (prawidłowy wynik)
u 4 (5 zmian). Na 15 badań w 13 przypadkach zaobserwowano wymywanie się radiofarmaceutyku ze zmiany, które sugeruje łagodny
charakter zmiany. Operowano trzech chorych ze zmianami gromadzącymi MIBI-Tc99m w badaniu scyntygraficznym, niemniej wynik
badania histopatologicznego był we wszystkich przypadkach prawidłowy. Zaobserwowano, że interpretacja obrazów tarczycy SPECT/
/CT z MIBI-Tc99m uzyskiwanych metodą wymywania jest łatwiejsza i czytelniejsza niż w badaniu planarnym. U 3 z pozostałych 5 chorych
dane kliniczne nie zwiększają obecnie podejrzenia raka, u 2 nie kontynuowano obserwacji.
Wnioski: Ocena scyntygraficzna tarczycy wykonywana z zastosowaniem SPECT/CT z MIBI-Tc99m metodą wymywania może być pomoc-
na w diagnostyce różnicowej guzków tarczycy. (Endokrynol Pol 2010; 61 (5): 422–426)
Słowa kluczowe: Sestamibi znakowane technetem 99, guzki tarczycy, SPECT/CT
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Introduction
Thyroid cancer diagnosis is based mainly on fine needle
aspiration biopsy (FNAB) performed under ultrasonog-
raphy guidance [1]. In cases of an inconclusive FNAB
result, when there is no clear evidential data to support
the existence of a malignant lesion, or due to any other
reasons such as the patient’s age or coexisting diseases,
which make the decision process difficult, the question
arises whether the patient should be followed up or
should be encouraged to undergo surgery treatment.
The utility of nuclear medicine techniques in resolv-
ing these questions seems to be underestimated by en-
docrinology departments in Poland. Obviously the most
common form of imaging modality is ultrasonography
examination, which is mostly employed in diagnosis
and therapeutic decisions in patients with nontoxic
nodular goiter. Sometimes, however, conventional thy-
roid gland scintigraphy is used when endocrinologists
and nuclear medicine specialists look for possible hy-
perfunctioning nodules which exhibit diminished ma-
lignancy risk [2]. Additional methods, such as scintig-
raphy with MIBI-Tc99m, are rarely used in everyday prac-
tice. This oncophilic tracer is mainly used in previously
diagnosed thyroid malignancy but not in cases of be-
nign thyroid goiter [3–11].
Recent publications which highlight the usefulness
of MIBI-Tc99m in the decision process and the emergence
of new hybrid equipment encouraged us to conduct the
study [12, 13] to raise the question of whether MIBI-
Tc99 might be the useful in future in differential diagno-
sis of thyroid nodules. First, we wanted to evaluate the
delayed SPECT images.
Material and methods
Three specialists trained in endocrinology referred pa-
tients, in whom indications for thyroid surgery were not
clear, to our nuclear medicine department. These includ-
ed patients with non-diagnostic or inconclusive FNAB,
advanced age, the presence of concomitant disorders, the
presence of many nodules, or patients who were reluc-
tant to undergo surgery as a method of treatment.
The study comprised 12 patients (14 F, 1 M) aged an
average of 63.5 (54–75) years. Nine of them suffered
from nodular goiter, two had Hashimoto thyroiditis and
one had toxic nodular goiter. In all patients, an ultra-
sonography examination and a subsequent FNAB was
performed in 2009. All had normal thyroid function, and
one patient was treated with antithyroid drugs due to
a toxic nodular goiter. Two suffered from recurrent goi-
ter and had had previous subtotal thyroidectomy. FNAB
in seven cases was normal, in two cases it revealed fol-
licular tumour, non-diagnostic results were obtained in
two cases, and suspicious cells in one case. The relative
contraindications to surgery were: advanced age, lung
cancer in one case, arterial hypertension in two cases,
and diabetes in one case. Two patients had diagnosed
rheumatoid arthritis (one with systemic lupus erythe-
matosus). In ultrasonography examination, lesion di-
ameter was usually more than 10 mm (the biggest le-
sion diameter was 19 mm). There were many nodules
present in five cases, three patients had microcalcifica-
tions on sonography, in two patients there was a pal-
pable lymph node, and one patient had a “cold” nod-
ule in scintigraphy. Ten out of twelve refused surgery
as the treatment method.
Acquisition protocol
The patients were given an intravenous injection of
700–800MBq MIBI (Hexakis 2-Methoxy Isobutyl Isoni-
trile) labelled with Tc99m. Five minutes later, planar and
then SPECT/CT acquisition was performed with
a SPECT/CT gamma camera Infinia Hawkeye 4 with Xe-
leris clinical software. The patient was in the supine
position with her/his arm down during two phases of
the study. Two hours after the tracer injection, the same
procedure was repeated as a delayed phase. During the
two hours between both acquisitions the patient was
encouraged to drink fluids to clear the background.
The lesion with focally increased activity in scin-
tigraphy was processed. The region of interest (ROI)
was manually drawn on the lesion (T). Then, the se-
lected region was projected and pasted to the back-
ground (B), situated outside of the thyroid in early and
delayed studies for every patient. Subsequently, aver-
age ROI counts on the lesion in the early phase were
divided by average ROI counts on the background in
10 minutes (tumour to background ratio in 10 minutes-
TBR10). Analogically, the same procedure was repeat-
ed in a delayed study (tumour to background ratio in
120 minutes-TBR120). Washout was calculated as
a ratio (T10-T120dc)/T10 where dc means decay cor-
rection exponential.
The protocol used for the planar study was as fol-
lows: matrix 256 × 256, zoom 2 with anterior view of
the neck, time acquisition as needed to acquire 700,000
counts. The protocol used for the SPECT study was as
follows: matrix 128 × 128, 20 sec/projection, zoom 2,
tomo mode H. Immediately after SPECT acquisition, the
CT scans (140 kV, 2.5 mA) were acquired.
As well as the nuclear medicine study, an ultrasonog-
raphy examination was performed for correlation with
scintigraphic findings. Patient documentation was col-
lected and analyzed and the patients were encouraged
to contact the department. Patients with increased fo-
cal lesion uptake were referred to surgery if possible or
continued further follow-up.
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Results
Positive results (increased tracer uptake) in thyroid le-
sions were obtained in 8 patients, (10 lesions) and neg-
ative results (normal uptake), which suggested a diag-
nosis of benign lesion, in 4 patients (5 lesions). TBR10
varied from 2.07 to 3.14; TBR120 was found to be 0.37–
–15.42.
Washout ratios in two cases were below zero, which
means that the activity in the lesion increased over time
(–0.08 and –0.7, respectively). In the remaining cases,
washout ratio ranged from 0.08 to 0.76, which means
that MIBI-Tc99m was pumped out from cells. It was no-
ticed that the images obtained with the SPECT/CT wash-
out method were clearer and easier to read than were those
obtained from planar examination (Fig. 1A–E).
Three patients with positive results underwent sur-
gery and all had benign histopathology results after the
operation. One patient with a toxic nodular goiter ac-
cepted radioiodine treatment as an alternative method
Figure 1. A lesion with increased activity MIBI-Tc99m, which can
be seen exclusively in a coronal projection of SPECT/CT. A. Planar
study in early phase; B. Planar study in delayed phase; C. SPECT/
/CT study, coronal projection; D. SPECT/CT study, sagittal
projection; E. SPECT/CT study, transverse projection
Rycina 1. Ognisko o wzmożonej aktywności MIBI-Tc99m widoczne
wyłącznie w badaniu SPECT/CT w projekcji czołowej. A. Badanie
planarne w fazie wczesnej; B. Badanie planarne w fazie późnej; C.
Badanie SPECT/CT, przekrój czołowy; D. Badanie SPECT/CT,
przekrój strzałkowy; E. Badanie SPECT/CT, przekrój poprzeczny
A B
C D
E
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to surgery after negative results of the MIBI-Tc99m ex-
amination. Two patients with an increased tracer accu-
mulation are continuing follow-up because one does
not agree to surgery and the other has contra-indica-
tions for surgery.
Discussion
A clinician who is about to decide whether to recom-
mend a patient with thyroid nodule for thyroid sur-
gery treatment may encounter various obstacles that
can influence the final decision. They may be medical
reasons such as: inconclusive or non-diagnostic FNAB
results, advanced patient age, or coexisting diseases or
it may be the patient who disagrees to undergoing sur-
gery. Patients nowadays have many more sources of
information and they ask physicians for more detailed
data to legitimate radical treatment like thyroid surgery.
During the last decade great progress concerning tech-
nical possibilities has been made, which may influence
the diagnostic process per se.
In everyday practice, a traditional thyroid scan is
two-dimensional. Three-dimensional SPECT projec-
tions are also becoming widespread. Moreover, it is
possible to co-register function (SPECT) and structure
(CT) in one SPECT/CT device [12]. Usually, the power
of the hybrid equipment is used for “major” indications
such as neuroendocrine tumours or parathyroid gland
localization, but one has to bear in mind that in some
clinical situations fusion imaging may be of great value
in the differential diagnosis process of thyroid nodules
[13–16].
In conventional nuclear medicine, MIBI-Tc99m is
a well established tumour-seeking agent. Its value has
been shown in many publications [17–23]. MIBI-Tc99m
has good characteristics for in vivo tumour imaging,
which has been proven in many experimental culture
studies [17]. An experimental study by Crane proved
that the highest uptake was at the periphery of the tu-
mour while the centre of the tumour showed less re-
tention. It is understandable because the centre of the
tumour is often acellular and may be filled with necrotic
debris.
MIBI-Tc99m exhibits a complicated tumour uptake
due to the biochemical characteristics of MIBI-Tc99m
itself (positive cationic charge and lipophilicity) and due
to features of the tissue characteristic (local blood flow,
transcapillary exchange, interstitial transport, the num-
ber of mitochondria). The tracer is actively taken up by
mitochondria and passively transferred across the cell
membrane [17, 18]. In the last few years the relation-
ship between multidrug-resistant (MDR1) phenotype
and MIBI-Tc99m scanning has been intensively investi-
gated in many oncological fields [19–23]. Some publi-
cations [20–22] reveal an attempt to quantify the tumour
by background ratio and/or washout rate. This interest
is shared by authors of papers dealing with the appli-
cation of MIBI-Tc99m scintigraphy in the assessment of
thyroid nodules [2–6].
In clinical practice, the dilemma between a wait-and-
see attitude and surgery as the best method of treat-
ment may be insolvable. The group of patients described
in the present study may serve as an example. When
there are such factors as advanced age, chronic diseas-
es which make the risk of operation higher, inconclu-
sive FNAB results, the presence of many nodules which
are not large, and strengthened by patients’ reluctance
to undergo surgery, there is a need for an additional
technique. From this perspective, negative MIBI-Tc99m
may be crucial in the process of excluding malignancy.
It brings important input, both for clinicians and pa-
tients. Such support we gained, however, only in four
patients from the investigated group. Thus we intend-
ed to analyze the washout of the radiopharmaceutical
from the nodule by SPECT/CT imaging.
SPECT/CT is a new tool which helps to visualize
abnormal thyroid lesions better. It also provides nucle-
ar medicine practitioners with much more data to anal-
yse and interpret than they would obtain from a planar
study. However, it may also lead to false positive con-
clusions (which might have happened in our group).
Only for three out of the eight patients did we have
pathology evaluations, done postoperatively, and in all
cases they were benign. Also, for three of the five re-
maining MIBI-positive cases, for whom the data from
the follow up were available, it did not increase the sus-
picion of malignancy.
The problem is that there is no experience with as-
sessing MIBI-Tc99m SPECT/CT imaging with quantita-
tive methods. As a result, there may be some discor-
dance between medical centres in the interpretation of
the data. In literature, timing and calculating the tu-
mour/background and washout ratios (the latter less
often) differs from study to study. For example, Shar-
ma compared the region of increased uptake with the
second region of interest, which was drawn just below
the nodule for background activity 30 minutes after in-
jection [24]. Other authors calculated activity after
10 minutes or used different protocols for the tumour/
/background ratio. There is a need for standardization
of image interpretation across the literature. This opin-
ion is expressed by Hurtado-López in one of the last
issues of Nuklearmedizin [25]
Conclusions
We consider that the majority of our patients could be
considered to have benign thyroid nodules on the ba-
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support the use of MIBI-Tc99m in the evaluation of inde-
terminate thyroid nodules. To validate the hypothesis
that MIBI-Tc99m can be used to exclude malignancy in
lesions indeterminate by FNAB, we propose the use of
SPECT-CT derived images and standardized evaluation
criteria.
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